Adjusted multivariable analysis of risk factors for MC-TA-TMA among recipients of allogeneic HCT (n = 198)
| Factors . | Cho criteria . | Jodele criteria . | ||
|---|---|---|---|---|
| Adjusted OR (95% CI) . | P . | Adjusted OR (95% CI) . | P . | |
| ≥2 HCT | 8.5 (1.4-50.3) | .02 | 10.3 (1.4-74.3) | .02 |
| Active grade 3/4 aGVHD | 9.8 (2.1-45.9) | .004 | 14.1 (2.1-92.7) | .006 |
| Active infection | 140.2 (32.3-608.6) | <.0001 | 44.4 (8.0-245.5) | <.0001 |
| Factors . | Cho criteria . | Jodele criteria . | ||
|---|---|---|---|---|
| Adjusted OR (95% CI) . | P . | Adjusted OR (95% CI) . | P . | |
| ≥2 HCT | 8.5 (1.4-50.3) | .02 | 10.3 (1.4-74.3) | .02 |
| Active grade 3/4 aGVHD | 9.8 (2.1-45.9) | .004 | 14.1 (2.1-92.7) | .006 |
| Active infection | 140.2 (32.3-608.6) | <.0001 | 44.4 (8.0-245.5) | <.0001 |
Seven patients with graft failure were excluded from the analysis. Active infection included bacterial, viral, and/or fungal infection within 30 days of MC-TA-TMA. Firth’s penalized maximum likelihood estimation was performed for the model.